Restless legs syndrome/Willis Ekbom disease: Evaluation and treatment

References

• Abetz, L., Arbuckle, R., Allen, R.P., Garcia-Borreguero, D., Hening, W., Walters, A.S., … Kirsch, J.M. (2006). The reliability, validity and responsiveness of the International Restless Legs Syndrome Study Group rating scale and subscales in a clinical-trial setting. Sleep Medicine, 7, 340–349.
   PubMed Web of Science ®Google Scholar
• Akpinar, S. (1982). Treatment of restless legs syndrome with levodopa plus benserazide [letter]. Archives of Neurology, 39, 739.
   PubMed Web of Science ®Google Scholar
• Allen, R.P., Adler, C.H., Du, W., Butcher, A., Bregman, D.B., & Earley, C.J. (2011). Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: A multi-centred, placebo-controlled preliminary clinical trial. Sleep Medicine, 12, 906–913. doi: S1389-9457(11)00232-2[pii]10.1016/j.sleep.2011.06.009
   PubMed Web of Science ®Google Scholar
• Allen, R.P., Barker, P.B., Horska, A., & Earley, C.J. (2013). Thalamic glutamate/glutamine in restless legs syndrome: Increased and related to disturbed sleep. Neurology, 80, 2028–2034. doi: 10.1212/WNL.0b013e318294b3f6
   PubMed Web of Science ®Google Scholar
• Allen, R.P., Barker, P.B., Wehrl, F., Song, H.K., & Earley, C.J. (2001). MRI measurement of brain iron in patients with restless legs syndrome. Neurology, 56, 263–265.
   PubMed Web of Science ®Google Scholar
• Allen, R.P., Chen, C., Garcia-Borreguero, D., Polo, O., DuBrava, S., Miceli, J., … Winkelman, J.W. (2014). Comparison of pregabalin with pramipexole for restless legs syndrome. New England Journal of Medicine, 370, 621–631. doi: 10.1056/NEJMoa1303646
   PubMed Web of Science ®Google Scholar
• Allen, R.P., & Earley, C.J. (1996). Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep, 19, 205–213.
   PubMed Web of Science ®Google Scholar
• Allen, R.P., & Earley, C.J. (2007). The role of iron in restless legs syndrome. Movement Disorders, 22, S440–S448.
   Web of Science ®Google Scholar
• Allen, R.P., La Buda, M.C., Becker, P., & Earley, C.J. (2002). Family history study of the restless legs syndrome. Sleep Medicine, 3(Suppl), S3–7.
   Google Scholar
• Allen, R.P., Picchietti, D.L., Garcia-Borreguero, D., Ondo, W.G., Walters, A.S., Winkelman, J.W., … Lee, H. B. (in press). Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria—history, rationale, description, and significance. Sleeep Medicine.
   Google Scholar
• Allen, R.P., Picchietti, D., Hening, W.A., Trenkwalder, C., Walters, A.S., & Montplaisir, J. (2003). Restless legs syndrome: Diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Medicine, 4, 101–119.
   PubMed Web of Science ®Google Scholar
• Allen, R.P., Stillman, P., & Myers, A.J. (2010). Physician- diagnosed restless legs syndrome in a large sample of primary medical care patients in western Europe: Prevalence and characteristics. Sleep Medicine, 11, 31–37. doi: S1389-9457 (09)00157-9[pii]10.1016/j.sleep.2009.03.007
   PubMed Web of Science ®Google Scholar
• Allen, R.P., Walters, A.S., Montplaisir, J., Hening, W., Myers, A., Bell, T.J., & Ferini-Strambi, L. (2005). Restless legs syndrome prevalence and impact: REST general population study. Archives of Internal Medicine, 165, 1286–1292.
   PubMed Web of Science ®Google Scholar
• Barton, A., Bowie, J., & Ebmeire, M. (1990). Low plasma iron status and akathisia. Journal of Neurology, Neurosurgery and Psychiatry, 53, 671–674.
   PubMed Web of Science ®Google Scholar
• Bassetti, C.L., Mauerhofer, D., Gugger, M., Mathis, J., & Hess, C.W. (2001). Restless legs syndrome: A clinical study of 55 patients. European Neurology, 45, 67–74.
   PubMed Web of Science ®Google Scholar
• Bayard, M., Bailey, B., Acharya, D., Ambreen, F., Duggal, S., Kaur, T., … Tudiver, F. (2011). Bupropion and restless legs syndrome: A randomized controlled trial. Journal of the American Board of Family Medicine, 24, 422–428. doi: 24/4/422[pii]10.3122/jabfm.2011.04.100173
   PubMed Web of Science ®Google Scholar
• Beard, G. (1880). A Practical Treatise on Nervous Exhaustion. New York: William Wood.
   Google Scholar
• Benes, H., Garcia-Borreguero, D., Ferini-Strambi, L., Schollmayer, E., Fichtner, A., & Kohnen, R. (2012). Augmentation in the treatment of restless legs syndrome with transdermal rotigotine. Sleep Medicine. doi: 10.1016/j.sleep. 2011.09.016
   Google Scholar
• Bogan, R.K., Fry, J.M., Schmidt, M.H., Carson, S.W., & Ritchie, S.Y. (2006). Ropinirole in the treatment of patients with restless legs syndrome: A US-based randomized, double-blind, placebo-controlled clinical trial. Mayo clinic Procedings, 81, 17–27.
   PubMed Web of Science ®Google Scholar
• Boghen, D., Lamothe, L., Elie, R., Godbout, R., & Montplaisir, J. (1986). The treatment of the restless legs syndrome with clonazepam: A prospective controlled study. Canadian Journal of Neurological Science, 13, 245–247.
   PubMed Web of Science ®Google Scholar
• Brown, K.W., Glen, S.E., & White, T. (1987). Low serum iron status and akathisia. Lancet, 1, 1234–1236.
   Google Scholar
• Catoire, H., Dion, P.A., Xiong, L., Amari, M., Gaudet, R., Girard, S.L., … Rouleau, G.A. (2011). Restless legs syndrome-associated MEIS1 risk variant influences iron homeostasis. Annals of Neurology, 70, 170–175. doi: 10.1002/ana.22435
   PubMedGoogle Scholar
• Chengappa, K.N., Baker, R.W., & Baird, J. (1993). Iron for chronic and persistent akathisia. Journal of Clinical Psychiatry, 54, 320–321.
   Google Scholar
• Connor, J.R., Boyer, P.J., Menzies, S.L., Dellinger, B., Allen, R.P., & Earley, C.J. (2003). Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology, 61, 304–309.
   PubMed Web of Science ®Google Scholar
• Connor, J.R., Wang, X., Allen, R.P., Beard, J., Wiesinger, J.A., Felt, B.T., & Earley, C.J. (2009). Altered dopaminergic profile in the putamen and substantia nigra in restless leg syndrome. Brain, 132, 2403–2412. doi: awp125[pii]10.1093/brain/awp125
   PubMed Web of Science ®Google Scholar
• Corrigan, M.H., Denahan, A.Q., Wright, C.E., Ragual, R.J., & Evans, D.L. (2000). Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depression and Anxiety, 11, 58–65.
   PubMed Web of Science ®Google Scholar
• Earley, C.J., & Allen, R.P. (1996). Pergolide and carbidopa/ levodopa treatment of the restless legs syndrome and periodic leg movements in sleep in a consecutive series of patients. Sleep, 19, 801–810.
   PubMedGoogle Scholar
• Earley, C.J., & Allen, R.P. (2006). Restless legs syndrome augmentation associated with tramadol. Sleep Medicine, 7, 592–593.
   PubMed Web of Science ®Google Scholar
• Earley, C.J., Heckler, D., & Allen, R.P. (2001). IV iron treatment for the restless legs syndrome (RLS). Sleep, 24, A359.
   Web of Science ®Google Scholar
• Earley, C.J., Horska, A., Mohamed, M.A., Barker, P.B., Beard, J.L., & Allen, R.P. (2009). A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndrome. Sleep Medicine, 10, 206–211.
   PubMed Web of Science ®Google Scholar
• Earley, C.J., Kuwabara, H., Wong, D.F., Gamaldo, C., Salas, R., Brasic, J., … Allen, R.P. (2011). The dopamine transporter is decreased in the striatum of subjects with restless legs syndrome. Sleep, 34, 341–347.
   PubMed Web of Science ®Google Scholar
• Earley, C.J., Kuwabara, H., Wong, D.F., Gamaldo, C., Salas, R.E., Brasic, J.R., … Allen, R.P. (2013). Increased synaptic dopamine in the putamen in restless legs syndrome. Sleep, 36, 51–57. doi: 10.5665/sleep.2300
   PubMed Web of Science ®Google Scholar
• Ekbom, K.A. (1945). Restless Legs (H. Frey, Trans.). Stockholm: Ivar Haeggströms.
   Google Scholar
• Gamaldo, C., Benbrook, A.R., Allen, R.P., Oguntimein, O., & Earley, C.J. (2009). Evaluating daytime alertness in individuals with restless legs syndrome (RLS) compared to sleep restricted controls. Sleep Medicine, 10, 134–138.
   PubMed Web of Science ®Google Scholar
• Garcia-Borreguero, D. (2004). Augmentation: Understanding a key feature of RLS. Sleep Medicine, 5, 5–6.
   PubMed Web of Science ®Google Scholar
• Garcia-Borreguero, D., Hogl, B., Ferini-Strambi, L., Winkelman, J., Hill-Zabala, C., Asgharian, A., & Allen, R. (2012). Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis- Ekbom disease): Results from a prospective, multicenter study over 66 weeks. Movement Disorders, 27, 277–283. doi: 10.1002/mds.24889
   PubMed Web of Science ®Google Scholar
• Garcia-Borreguero, D., Kohnen, R., Silber, M.H., Winkelman, J.W., Earley, C.J., Hogl, B., … Allen, R.P. (2013). The long-term treatment of restless legs syndrome/Willis- Ekbom disease: Evidence-based guidelines and clinical consensus best practice guidance: A report from the International Restless Legs Syndrome Study Group. Sleep Medicine, 14, 675–684. doi: 10.1016/j.sleep.2013.05.016
   PubMed Web of Science ®Google Scholar
• Garcia-Borreguero, D., Larrosa, O., de la Llave, Y., Verger, K., Masramon, X., & Hernandez, G. (2002). Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology, 59, 1573–1579.
   PubMed Web of Science ®Google Scholar
• Garcia-Borreguero, D., Montagna, P., Trenkwalder, C. group, R. R. s. (2003). Ropinirole is Effective in the Treatment of Restless Legs Syndrome (RLS): A Double-Blind Placebo-Controlled 12-Week Study Conducted in 10 Countries. Neurology, 60(suppl 1), A11–12.
   Google Scholar
• Giorgi, L., Ritchie, S.Y., & Kirsch, J.M. (2006). Efficacy and tolerability of ropinirole in patients with restless legs syndrome and a baseline IRLS total score > or = 24 points – Data from the ropinirole clinical trial programme. Current Medical Research Opinion, 22, 1867–1877.
   PubMed Web of Science ®Google Scholar
• Grote, L., Leissner, L., Hedner, J., & Ulfberg, J. (2009). A randomized, double-blind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Movement Disorders, 24, 1445–1452.
   PubMed Web of Science ®Google Scholar
• Hening, W.A., Walters, A.S., Wagner, M., Rosen, R., Chen, V., Kim, S., … Thai, O. (1999). Circadian rhythm of motor restlessness and sensory symptoms in the idiopathic restless legs syndrome. Sleep, 22, 901–912.
   PubMed Web of Science ®Google Scholar
• Hoque, R., & Chesson, A.L., Jr. (2010). Pharmacologically induced/exacerbated restless legs syndrome, periodic limb movements of sleep, and REM behavior disorder/REM sleep without atonia: Literature review, qualitative scoring, and comparative analysis. Journal of Clinical Sleep Medicine, 6, 79–83.
   PubMed Web of Science ®Google Scholar
• Inami, Y., Horiguchi, J., Nishimatsu, O., Sasaki, A., Sukegawa, T., Katagiri, H., & Yamawaki, S. (1997). A polysomnographic study on periodic limb movements in patients with restless legs syndrome and neuroleptic-induced akathisia. Hiroshima Journal of Medical Science, 46, 133–141.
   Google Scholar
• Inoue, Y., Uchimura, N., Kuroda, K., Hirata, K., & Hattori, N. (2012). Long-term efficacy and safety of gabapentin enacarbil in Japanese restless legs syndrome patients. Progress in Neuropsychopharmacology and Biological Psychiatry, 36, 251–257. doi: 10.1016/j.pnpbp.2011.10.009
   PubMed Web of Science ®Google Scholar
• International Restless Legs Syndrome Study Group. (2003). Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Medicine, 4, 121–132.
   PubMed Web of Science ®Google Scholar
• Kallweit, U., Siccoli, M.M., Poryazova, R., Werth, E., & Bassetti, C.L. (2009). Excessive daytime sleepiness in idiopathic restless legs syndrome: Characteristics and evolution under dopaminergic treatment. European Neurology, 62, 176–179. doi: 000228261 [pii]10.1159/000228261
   PubMed Web of Science ®Google Scholar
• Lee, D.O., Ziman, R.B., Perkins, A.T., Poceta, J.S., Walters, A.S., Barrett, R.W., & Group, X.P.S. (2011). A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome. Journal of Clinical Sleep Medicine, 7, 282–292. doi: 10.5664/JCSM.1074
   PubMed Web of Science ®Google Scholar
• Lee, H.B., Hening, W.A., Allen, R.P., Kalaydjian, A.E., Earley, C.J., Eaton, W.W., & Lyketsos, C.G. (2008). Restless legs syndrome is associated with DSM-IV major depressive disorder and panic disorder in the community. Journal of Neuropsychiatry and Clinal Neuroscience, 20, 101–105.
   PubMed Web of Science ®Google Scholar
• Lugaresi, E., Coccagna, G., Berti Ceroni, G., & Ambrosetto, C. (1968). Restless legs syndrome and nocturnal myoclonus. In H. Gastaut, E. Lugaresi & G. Berti Ceroni (Eds), The Abnormalites of Sleep in Man (pp. 285–294). Bologna: Aulo Gaggi Editore.
   Google Scholar
• Matthews, W.B. (1979). Treatment of the restless legs syndrome with clonazepam [letter]. British Medical Journal, 1, 751.
   Google Scholar
• Montplaisir, J., Boucher, S., Poirier, G., Lavigne, G., Lapierre, O., & Lesperance, P. (1997). Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: A study of 133 patients diagnosed with new standard criteria. Movement Disorders, 12, 61–65.
   PubMed Web of Science ®Google Scholar
• Montplaisir, J., Lorrain, D., & Godbout, R. (1991). Restless legs syndrome and periodic leg movements in sleep: The primary role of dopaminergic mechanism. European Neurology, 31, 41–43.
   PubMed Web of Science ®Google Scholar
• Nardone, R., Ausserer, H., Bratti, A., Covi, M., Lochner, P., Marth, R., & Tezzon, F. (2006). Cabergoline reverses cortical hyperexcitability in patients with restless legs syndrome. Acta Neurologica Scandinavica, 114, 244–249.
   Google Scholar
• Oertel, W., Trenkwalder, C., Benes, H., Ferini-Strambi, L., Hogl, B., Poewe, W., … Garcia-Borreguero, D. (2011). Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: A 5-year open-label extension study. Lancet Neurologyogy, 10, 710–720. doi: 10.1016/S1474-4422(11)70127-2
   PubMed Web of Science ®Google Scholar
• Ondo, W.G. (2005). Methadone for refractory restless legs syndrome. Movement Disorders, 20, 345–348.
   PubMed Web of Science ®Google Scholar
• Ondo, W.G. (2010). Intravenous iron dextran for severe refractory restless legs syndrome. Sleep Medicine, 11, 494–496. doi: S1389-9457(10)00036-5 [pii] 10.1016/j.sleep.2009. 12.002
   PubMed Web of Science ®Google Scholar
• Oppenheim, H. (1923). Lehrbuch der nervenkrankheiten. Berlin: Karger.
   Google Scholar
• Pantaleo, N.P., Hening, W.A., Allen, R.P., & Earley, C.J. (2010). Pregnancy accounts for most of the gender differences in prevalence of familial RLS. Sleep Medicine, 11, 310–313.
   PubMed Web of Science ®Google Scholar
• Picchietti, D., Allen, R.P., Walters, A.S., Davidson, J.E., Myers, A., & Ferini-Strambi, L. (2007). Restless legs syndrome: Prevalence and impact in children and adolescents – The Peds REST study. Pediatrics, 120, 253–266.
   PubMed Web of Science ®Google Scholar
• Rizzo, G., Manners, D., Testa, C., Tonon, C., Vetrugno, R., Marconi, S., … Lodi, R. (2013). Low brain iron content in idiopathic restless legs syndrome patients detected by phase imaging. Movement Disorders. doi: 10.1002/mds.25576
   Google Scholar
• Scalise, A., Cadore, I.P., & Gigli, G.L. (2004). Motor cortex excitability in restless legs syndrome. Sleep Medicine, 5, 393–396.
   PubMed Web of Science ®Google Scholar
• Scalise, A., Pittaro-Cadore, I., Janes, F., Marinig, R., & Gigli, G.L. (2010). Changes of cortical excitability after dopaminergic treatment in restless legs syndrome. Sleep Medicine, 11, 75–81. doi: S1389-9457(09)00222-6 [pii] 10.1016/j.sleep.2009. 05.003
   Google Scholar
• Schmidauer, C., Sojer, M., Seppi, K., Stockner, H., Hogl, B., Biedermann, B., … Poewe, W. (2005). Transcranial ultrasound shows nigral hypoechogenicity in restless legs syndrome. Annals of Neurology, 58, 630–634.
   PubMed Web of Science ®Google Scholar
• Selak, I. (2001). Pregabalin (Pfizer). Current Opinion in Investigational Drugs, 2, 828–834.
   PubMedGoogle Scholar
• Silver, N., Allen, R.P., Senerth, J., & Earley, C.J. (2011). A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome. Sleep Medicine, 12, 440–444. doi: S1389-9457(10)00371-0 [pii] 10.1016/j.sleep.2010.11.002
   PubMed Web of Science ®Google Scholar
• Stefansson, H., Rye, D.B., Hicks, A., Petursson, H., Ingason, A., Thorgeirsson, T.E., … Stefansson, K. (2007). A genetic risk factor for periodic limb movements in sleep. New England Journal of Medicine, 357, 639–647.
   PubMed Web of Science ®Google Scholar
• Stiasny-Kolster, K., Kohnen, R., Moller, J.C., Trenkwalder, C., & Oertel, W.H. (2006). Validation of the ‘L-DOPA test’ for diagnosis of restless legs syndrome. Movement Disorders, 21, 1333–1339.
   PubMed Web of Science ®Google Scholar
• Tergau, F., Wischer, S., & Paulus, W. (1999). Motor system excitability in patients with restless legs syndrome. Neurology, 52, 1060–1063.
   PubMed Web of Science ®Google Scholar
• Trenkwalder, C., Benes, H., Grote, L., Garcia-Borreguero, D., Hogl, B., Hopp, M., … Group, R.S. (2013). Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: A double- blind, randomised, placebo-controlled trial with an open-label extension. Lancet Neurology, 12, 1141–1150. doi: 10.1016/S1474-4422(13)70239-4
   PubMed Web of Science ®Google Scholar
• Vetrugno, R., La Morgia, C., D’Angelo, R., Loi, D., Provini, F., Plazzi, G., & Montagna, P. (2007). Augmentation of restless legs syndrome with long-term tramadol treatment. Movement Disorders, 22, 424–427.
   PubMed Web of Science ®Google Scholar
• Walters, A.S., Aldrich, M.A., Allen, R.P., Ancoli-Israel, S., Buchholz, D., Chockroverty, S., … Zucconi, M. (1995). Toward a better definition of the restless legs syndrome. Movement Disorders, 10, 634–642.
   PubMed Web of Science ®Google Scholar
• Walters, A.S., Ondo, W.G., Kushida, C.A., Becker, P.M., Ellenbogen, A.L., Canafax, D.M., & Barrett, R.W. (2009). Gabapentin enacarbil in restless legs syndrome: A phase 2b, 2-week, randomized, double-blind, placebo-controlled trial. Clinical Neuropharmacology, 32, 311–320.
   PubMed Web of Science ®Google Scholar
• Walters, A.S., Wagner, M.L., Hening, W.A., Grasing, K., Mills, R., Chokroverty, S., & Kavey, N. (1993). Successful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo. Sleep, 16, 327–332.
   PubMed Web of Science ®Google Scholar
• Wang, J., O’Reilly, B., Venkataraman, R., Mysliwiec, V., & Mysliwiec, A. (2009). Efficacy of oral iron in patients with restless legs syndrome and a low-normal ferritin: A randomized, double-blind, placebo-controlled study. Sleep Medicine.
   Google Scholar
• Willis, T. (1683). Two Discourses Concerning the Soul of Brutes. London: Dring, Harper, & Leigh.
   Google Scholar
• Willis, T. (1685). The London Practice of Physick. London: Bassett & Crooke.
   Google Scholar
• Winkelmann, J., Czamara, D., Schormair, B., Knauf, F., Schulte, E.C., Trenkwalder, C., … Meitinger, T. (2011). Genome-wide association study identifies novel restless legs syndrome susceptibility loci on 2p14 and 16q12.1. PLoS Genetics, 7, e1002171. doi: 10.1371/journal.pgen.1002171
   PubMed Web of Science ®Google Scholar
• Winkelmann, J., Prager, M., Lieb, R., Pfister, H., Spiegel, B., Wittchen, H.U., … Strohle, A. (2005). ‘Anxietas tibiarum’. Depression and anxiety disorders in patients with restless legs syndrome. Journal of Neurology, 252, 67–71.
   PubMed Web of Science ®Google Scholar
• Winkelman, J.W., Sethi, K.D., Kushida, C.A., Becker, P.M., Koester, J., Cappola, J.J., & Reess, J. (2006). Efficacy and safety of pramipexole in restless legs syndrome. Neurology, 67, 1034–1039.
   PubMed Web of Science ®Google Scholar
• Winkelmann, J., Schormair, B., Lichtner, P., Ripke, S., Xiong, L., Jalilzadeh, S., … Meitinger, T. (2007). Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nature Genetics, 39, 1000–1006.
   PubMed Web of Science ®Google Scholar
• Wittmaack, T. (1861). Pathologie und Therapie der Sensibilitatneurosen. Leipzig: Schafer.
   Google Scholar